Previous 10 | Next 10 |
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its Chief Manufacturing and Technology Officer Hemant Kumar, Ph.D. will participate in the upcoming Bioprocessing Summit Europe...
Genprex to Present at Bioprocessing Summit Conference PR Newswire Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies AUSTIN, Texas , March 13, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the ...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has announced its participation in two March conferences: the 35th annual Roth Conference and the BIO-Europe Spring Conference. The Roth Conference i...
2023-03-08 08:30:00 ET Summary The company’s diabetes gene therapy exhibited encouraging preclinical results in both the diabetic mouse model and non-human primate [NHP] model, improving glucose tolerance and reducing insulin requirements. The GPX-002/003 gene therapy could...
Genprex to Participate in March Investor and Industry Conferences PR Newswire Company to Showcase its Innovate Gene Therapy Programs in Oncology and Diabetes AUSTIN, Texas , March 8, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NAS...
Gainers: Lucira Health ( LHDX ) +255% . ContraFect ( CFRX ) +56% . AERWINS Technologies ( AWIN ) +52% . Asset Entities ( ASST ) +34% . Troika Media Group ( TRKA ) +30% . Moolec Science ( MLEC ) +26% . Fisker ( FSR ) +...
Gainers: Lucira Health ( LHDX ) +357% . ContraFect ( CFRX ) +75% . Moolec Science ( MLEC ) +29% . Werewolf ( HOWL ) +14% . The Pennant Group ( PNTG ) +16% . Losers: Genprex ( GNPX ) -17% . ETAO Internationl ( ET...
Genprex ( NASDAQ: GNPX ) entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 3.81M shares along with its warrants at a combined purchase price of $1.05/share in a registered direct offering. Warrants,...
Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor PR Newswire AUSTIN, Texas , Feb. 27, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage ge...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Postmodern Studio / Shutterstock.com Teladoc (NYSE: TDOC ) stock is on the move Thursday after getting an upgrade from SVB Securities . That upgrade has SVB Securities analysts boosting TDOC stock from a ...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...